5 reports

  • 7.1.5 RIZAPORT (RIZATRIPTAN BENZOATE)
  • 7.1.6 ONZETRA XSAIL (SUMATRIPTAN SUCCINATE)

SUBJECTS REPORTED PAIN RELIEF IN LESS THAN ## MINUTES, WITH ##% OF SUBJECTS REPORTING PAIN RELIEF WITHIN ONE HOUR OF ADMINISTRATION OF A SINGLE ##MG SUBCUTANEOUS DOSE OF IMITREX INJECTION.

  • Antimigraine
  • Allergan plc
  • Amgen Inc.
  • Eli Lilly & Co.
  • Pfizer Inc.
  • Effectiveness of Oral Triptans
  • GSK- Revenues from Imigran/Imitrex Migraine Drugs Brands

Scope of the report The report titled “Global Anti-Migraine Drugs Market: Trends and Opportunities (2014-2019)” provides an insight into migraine drugs with a special focus on Triptans. The report also includes the market value, segmentation, types of diagnosis and treatment for migraine. It also discusses key growth drivers...

  • Antimigraine
  • World
  • Endo International plc
  • Impax Laboratories, Inc.
  • Pfizer Inc.
  • 6.18.4. TARGET POPULATION

IN ADDITION, THE FILM PROVIDES RAPID PAIN RELIEF TO THE PATIENTS.

  • Antimigraine
  • North America
  • United States
  • Demand
  • Market Size
  • MTR-106 - DRUG PROFILE
  • LASMIDITAN SUCCINATE - DRUG PROFILE

Migraine - Pipeline Review, H2 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Migraine - Pipeline Review, H2 2017, provides an overview of the Migraine (Central Nervous System) pipeline landscape. Migraine is a disorder characterized by repeated attacks of severe...

  • Antimigraine
  • Pain Relief
  • Pharmaceutical
  • United States
  • Product Initiative

In a proof-of-concept clinical trial evaluating patients with frequent episodic migraine, ALD## demonstrated significant prevention of migraines, including complete migraine relief (##% suppression of migraine occurrence) in ##% to ##% of patients in any given month.

  • Antimigraine
  • Neurology
  • Pharmaceutical
  • World
  • Product Initiative